Genetic Signatures

Genetic Signatures Change in Working Capital

The Change in Working Capital of Genetic Signatures (GSS.AX) as of Oct 28, 2026 is 1.90 M AUD. In the previous year, Change in Working Capital was -2.55 M AUD — a change of -174.53% (higher).

Change in Working Capital

1.90 MAUD

YoY

-174.53%

Last updated:

Change in Working Capital of Genetic Signatures is 2026 1.90 M AUD. Change in Working Capital of Genetic Signatures was 2025 -2.55 M AUD. It decreases by -174.53% higher compared to the previous year.

The Genetic Signatures Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2019
-273,000.00 AUD
Jan 1, 2020
-8.44 M AUD
Jan 1, 2021
-1.63 M AUD
Jan 1, 2022
3.68 M AUD
Jan 1, 2023
-2.19 M AUD
Jan 1, 2024
4.20 M AUD
Jan 1, 2025
-2.55 M AUD
Jan 1, 2026
1.90 M AUD
The Genetic Signatures Change in Working Capital history
YEARChange in Working CapitalYoY
1.90 MAUD-174.53%
-2.55 MAUD-160.65%
4.20 MAUD-292.27%
-2.19 MAUD-159.33%
3.68 MAUD-326.23%
-1.63 MAUD-80.71%
-8.44 MAUD+2,991.94%
-273,000.00AUD-63.06%
-739,079.00AUD-2,175.37%
35,612.00AUD-105.82%
-611,661.00AUD+21.53%
-503,317.00AUD-2,852.92%
18,283.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Signatures stock

Change in Working Capital of Genetic Signatures is 1.90 M AUD in 2026.

Change in Working Capital of Genetic Signatures changed from -2.55 M AUD to 1.90 M AUD, representing a -174.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Genetic Signatures historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genetic Signatures

All Key Metrics — Genetic Signatures